1. USRDS. 2013 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the united states, national institutes of health, national institute of diabetes and digestive and kidney diseases. MD: Bethesda; 2013.
2. Epogen (epoetin alfa) package insert. Thousand Oaks, CA: Amgen, Inc; 2011.
3. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–43.
4. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2009;20:479–87.
5. Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405–16.